WeVote
Log In

Bill

Bill

S 4601

Relates to exempting school supplies from sales tax during a specified period each year

2025 Regular Session Introduced by Andrew Gounardes

The bill would allow certain drug manufacturers and wholesale distributors to supply dialysate drugs/devices for home dialysis to ESRD patients without a licensed pharmacist, under

REPORTED AND COMMITTED TO FINANCE
0
WeVote Research Nonpartisan
Bill Summary · S 4601

S 4601 — Summary

Note: The bill text provided for S 4601 concerns the licensing and distribution of dialysate drugs and devices for home dialysis, not the sale of school supplies. The introduced version proposes a pharmacist licensing exemption for certain manufacturers/distributors under specific conditions, with ongoing pharmacist oversight. The description below reflects the introduced content and its substantive provisions.

Overview and Intent

  • Purpose: To exempt certain drug manufacturers and wholesale drug distributors from the requirement to hold a licensed pharmacist when distributing dialysate drugs or devices needed for home dialysis for patients with end-stage renal disease (ESRD), under tightly defined safeguards.
  • Context: Aims to facilitate the distribution of essential dialysis-related drugs/devices while maintaining regulatory oversight through a licensed pharmacist’s involvement.

Key Provisions

  1. Exemption from pharmacist licensing
    • Manufacturers or wholesale drug distributors would not be required to be licensed pharmacists to distribute dialysate drugs or devices for home dialysis to ESRD patients, subject to conditions.
  2. Eligibility criteria for the exempt activity
    • The dialysate drugs/devices must be FDA-approved.
    • The distributing entity must be properly registered as a manufacturer or wholesale drug distributor.
    • Drugs/devices must be in original, sealed labeled packaging from the manufacturing facility.
    • Delivery must be by the manufacturer or its agent and only upon receipt of a physician’s order.
    • Delivery may be to:
      • the patient or the patient’s designee for self-administration, or
      • a healthcare provider or institution for administration or delivery of dialysis therapy.
    • The manufacturer must contract with a consultant pharmacist who is properly registered by the board to provide weekly quality assurance assessments of home dialysis drug storage and distribution.
  3. Ongoing oversight
    • Despite the exemption from pharmacist licensing, periodic oversight by a licensed pharmacist via the consultant pharmacist is required.
  4. Related licensing framework
    • The underlying statutory framework (P.L.2003, c.280) sections remain, with the exemption carved out specifically for the dialysate context under the conditions listed.

Affected Parties

  • Primary: Drug manufacturers and wholesale drug distributors engaged in supplying dialysate drugs/devices for home dialysis to ESRD patients.
  • Secondary: Patients with ESRD receiving home dialysis, physicians ordering the drugs/devices, and healthcare providers/institutions delivering dialysis therapy.
  • Oversight: A licensed pharmacist will oversee quality assurance weekly, albeit not as the distributing entity’s required license.

Procedural and Timeline Details

  • Status: Reported and committed to Finance (indicating passage through committee stages toward fiscal consideration).
  • Introduced: June 12, 2025.
  • Effective Date: First day of the third month after enactment.
  • Legislative Actions listed include referrals to Budget and Revenue and committees (dates shown in the materials).

Sponsor and Related Legislation

  • Sponsor: Senator Andrew Gounardes (primary).
  • Related bills: A 5921 (companion); S 4744 (prior-session).

Impact and Implications

  • Potential benefits: Streamlined distribution of essential dialysis-related drugs/devices for home therapy; potential access improvements for ESRD patients.
  • Safeguards: Maintains patient safety through FDA approval requirements, proper registration, packaging integrity, physician-directed delivery, and ongoing QA by a licensed pharmacist (via a contracted consultant pharmacist).

If you’d like, I can tailor this summary to emphasize either the regulatory mechanics, fiscal implications, or practical impacts on patients and providers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.